Association of adiponectin with hepatic steatosis: A study of 1,349 subjects in a random population sample

BMC Research Notes

Volumn 7, Issue 1, 2014, Pages

  Flechtner Mors, Marion ^a   George, Samuel N ^b   Oeztuerk, Suemeyra ^b   Haenle, Mark M ^b   Koenig, Wolfgang ^b   Imhof, Armin ^b   Boehm, Bernhard O ^b   Graeter, Tilmann ^b   Mason, Richard A ^c   Kratzer, Wolfgang ^b   Akinli, Atilla S ^b  

^a Institute of Epidemiology Ulm   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

Adipose tissue; Cross sectional studies; Fatty liver; NAFLD; Ultrasonography

Indexed keywords

ADIPONECTIN; ADIPOQ PROTEIN, HUMAN; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; AGED; BLOOD; BODY MASS; COMORBIDITY; CROSS-SECTIONAL STUDY; DRINKING BEHAVIOR; FATTY LIVER; FEMALE; GERMANY; HUMAN; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; METABOLISM; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; SMOKING;

ADIPONECTIN; ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; ALCOHOL DRINKING; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASES; BODY MASS INDEX; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; COMORBIDITY; CROSS-SECTIONAL STUDIES; FATTY LIVER; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; GERMANY; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; SMOKING; TRIGLYCERIDES;

EID: 84898442699     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-7-207     Document Type: Article

References (56)

1. NASH a global health problem. Sanyal AJ, Hepatol Res 2011 41 670 674
2. Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Tannapfel A, Denk H, Dienes HP, Langner C, Schirmacher P, Trauner M, Flott-Rahmel B, Virchows Arch 2011 458 511 523
3. Non-alcoholic fatty liver disease pathogenesis: the present and the future. Petta S, Muratore C, Craxi A, Dig Liver Dis 2009 41 615 625
4. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Farrell GC, Larter CZ, Hepatology 2006 43 2 Suppl 1 99 112
5. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Starley BQ, Calcagno CJ, Harrison SA, Hepatology 2010 51 1820 1832
6. The clinical availability of non-alcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in korean men: 5-years' prospective cohort study. Park SK, Seo MH, Shin HC, Ryoo JH, Hepatology 2013 57 1378 1383
7. Non-alcoholic fatty liver disease, a marker of subclinical atherosclerosis applicable only to metabolic syndrome?: Time to organize the connection between metabolism and atherosclerosis. Lee SP, J Cardiovasc Ultrasound 2012 20 124 125
8. Adiponectin, a key adipokine in obesity related liver diseases. Buechler C, Wanninger J, Neumeier M, World J Gastroenterol 2011 17 2801 2811
9. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M, Hepatology 2003 37 917 923 (Pubitemid 36397405)
10. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engeneered mice. Postic C, Girard J, J Clin Invest 2008 118 829 838 (Pubitemid 351364588)
11. Obesity affects the liver-the link between adipocytes and hepatocytes. Wree A, Kahraman A, Gerken G, Canbay A, Digestion 2011 83 124 133
12. Association of adiponectin and metabolic syndrome in women. Sanjari M, Khodashahi M, Gholamhoseinian A, Shokooki M, J Res Med Sci 2011 16 1532 40
13. Association of hypoadiponectinemia with non-alcoholic fatty liver disease in urban south Indians-(CURES-81). Gokulakrishnan K, Anjana RM, Indulekha K, Anuradha S, Mohan V, Indian J Med Res 2010 132 271 277
14. Adiponectin as a protective factor in hepatic steatosis. Mendez-Sanchez N, Chavez-Tapia NC, Villa AR, Sanchez-Lara K, Zamona-Valdes D, Ramos MH, Uribe M, World J Gastroenterol 2005 11 1737 1741 (Pubitemid 40520759)
15. Plasma adiponectin-an independent indicator of liver fat accumulation. Pisto P, Ukkola O, Santaniemi M, Kesäniemi YA, Metabolism 2011 60 1515 1520
16. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. Bugianesi E, Pagotto U, Manini R, Vanni E, Gastaldelli A, de Iasio R, Gentilcore E, Natale S, Cassader M, Rizzetto M, Pasquali R, Marchesini G, J Clin Endocrinol Metab 2005 90 3498 3504 (Pubitemid 41014319)
17. Gender differences of adiponectin levels develop during the progression of puberty and are relared to serum androgen levels. Böttner A, Kratsch J, Müller G, Kapellen TM, Blüher S, Keller E, Blüher M, Kiess W, J Clin Endocrinol Metab 2004 89 4053 4062
18. Influence of sex hormones on adiponectin expression in human adipocytes. Horenburg S, Fischer-Posovszky P, Debatin KM, Wabitsch M, Horm Metab Res 2008 40 779 786 (Pubitemid 352772691)
19. Hypoadiponectinemia in obese subjects with type II diabetes: A close association with central obesity indices. Mohammadzadeh G, Zarghami N, J Res Med Sci 2011 16 713 723
20. Relationships between circulating adiponectin levels and fat distribution in obese subjects. Kishida K, Kim KK, Funahashi T, Matsuzawa Y, Kang HC, Shimomura I, J Atheroscler Thromb 2011 18 592 595
21. Association of adiponectin with body fat distribution and insulin sensitivity in nondiabetic Hispanics and African-Americans. Hanley AJ, Bowden D, Wagenknecht LE, Balasubramanyam A, Langfeld C, Saad MF, Rotter JI, Guo X, Chen YD, Bryer-Ash M, Norris JM, Haffner SM, J Clin Endocrinol Metab 2007 92 2665 2671 (Pubitemid 47037374)
22. Long-term, progressive, aerobic training increases adiponectin in middle-aged, overweight, untrained males and females. Mujumdar PP, Duerksen-Hughes PJ, Firek AF, Hessinger DA, Scand J Clin Lab Invest 2011 71 101 107
23. A 7-d exercise program increases high-molecular weight adiponectin in obese adults. Kelly KR, Blaszczak A, Haus JM, Patrick-Melin A, Fealy CE, Solomon TP, Kalinski MI, Kirwan JP, Med Sci Sports Exerc 2012 44 69 74
24. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. Thoma C, Day CP, Trenell MI, J Hepatol 2012 56 255 266
25. Hypertension and hepatic steatosis. Brookes MJ, Igbal TH, Cooper BT, Curr Hypetens Rep 2008 10 182 187
26. The association between fatty liver disease and blood pressure in a population-based prospective longitudinal study. Lau K, Lorbeer R, Haring R, Schmidt CO, Wallaschofski H, Nauck M, John U, Baumeister SE, Völzke H, J Hypertens 2010 28 1829 1835
27. Nonalcoholic fatty liver disease is associated with blood pressure in hypertensive and nonhypertensive individuals from the general population with normal levels of alanine aminotransferase. Lopez-Suarez A, Guerrero JM, Elvirs-Gonzalez J, Beltran-Robles M, Canas-Hormigo F, Bascunana-Quirell A, Eur J Gastrenterol Hepatol 2011 23 1011 1017
28. The relationships of plasma adiponectin with a favorable lipid profile, decreased inflammation, and less ectopic fat accumulation depend on adiposity. Kantartzis K, Rittig K, Balletshofer B, Machann J, Schick F, Porubska K, Fritsche A, Häring HU, Stefan N, Clin Chem 2006 52 1934 1942 (Pubitemid 44470702)
29. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Yamauchi T, Kamon J, Ito Y, Suchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, Kadowaki T, Nature 2003 423 762 769 (Pubitemid 36735700)
30. Adiponectin is an important determinant of apoA-I catabolism. Verges B, Petit JM, Duvillard L, Dautin G, Florentin E, Galland F, Gambert P, Arterioscler Thromb Vasc Biol 2006 26 1364 1369 (Pubitemid 44305383)
31. Prevalence of the metabolic syndrome among US middle-aged and older adults with and without diabetes-a prliminary analysis of the NHANES 1999-2002 data. Lin SX, Pi-Sunyer EX, Ethn Dis 2007 17 35 39 (Pubitemid 46231361)
32. Anti-inflammatory and anti-atherogenic properties of adiponectin. Ohashi K, Ouchi N, Matszawa Y, Biochimie 2012 94 2137 2142
33. Adiponectin: key player in the adipose tissue-liver crosstalk. Moschen AR, Wieser V, Tilg H, Curr Med Chem 2012 19 5467
34. The fat-derived hormone adiponectin alleviates alcoholic and non-alcoholic fatty liver disease in mice. Xu A, Wang Y, Keshaw H, Xu L, Lam KS, Cooper GJ, J Clin Invest 2003 112 91 100 (Pubitemid 38056380)
35. Prospective study of serum adiponectin and incident metabolic syndrome: the ARIRANG Study. Kim JY, Ahn SV, Yoon JH, Koh SB, Yoon J, Yoo BS, Lee SH, Park JK, Choe KH, Guallar E, Diabetes Care 2012 36 1547 1553
36. A longitudinal analysis on associations of adiponectin levels with metabolic syndrome and carotid artery intima-media thickness. Juonala M, Saarikoski LA, Vikari JS, Oikonen M, Lehtimäki T, Lyytikäinen LP, Huupponen R, Magnussen CG, Koskinen J, Laitinen T, Taittonen L, Kähönen M, Kivimäki M, Raitakari OT, The Cardivascular Risk in Young Finns Study. Atherosclerosis 2011 217 234 239
37. Moderate alcohol consumption increases insulin sensitivity and ADIPOQ expression in postmenopausal women: a randomised, crossover trial. Joosten MM, Beulens JW, Kersten S, Hendriks HF, Diabetologia 2008 51 1375 1381
38. Effect of drinking on adiponectin in healthy men and women: a randomized intervention study of water, ethanol, red wine, and beer with or without alcohol. Imhof A, Plamper I, Maier S, Rischler G, Koenig W, Diabetes Care 2009 32 1101 1103
39. Relationship between alcohol consumption and serum adiponectin levels: the Takahata study-a cross-sectional study of a healthy Japanese population. Nishise Y, Saito T, Makino N, Okumoto K, Ito JI, Watanabe H, Saito K, Togashi H, Ikeda C, Kubota I, Daimon M, Kato T, Fukao A, Kawata S, J Clin Endocrinol Metab 2010 95 3828 3835
40. Association of hypoadiponectinemia with smoking habit in men. Iwashima Y, Katsuya T, Ishikawa K, Kida I, Ohishi M, Horio T, Ouchi N, Ohashi K, Kihara S, Funahashi T, Rakugi H, Ogihara T, Hypertension 2005 45 1094 1100 (Pubitemid 40770311)
41. Changes of serum adiponectin and soluable intercellular adhesion molecule-1 concentrations after smoking cessation. Tsai JS, Guo FR, Chen SC, Lue BH, Lee LT, Huang KC, Chen CY, Hung SH, Chuang LM, Chen CY, Clin Chem Lab Med 2012 50 1063 1069
42. Association of adiponectin rs266729 gene polymorphism with nonalcoholic fatty liver disease. Hashemi M, Hanafi Bojd H, Eskandari Nasab E, Bahari A, Hashemzehi NA, Shafieipour S, Narouie B, Taheri M, Ghavami S, Hepat Mon 2013 13 9527
43. Impact of sterol regulatory element-binding factor-1c polymorphism on incidence of nonalcoholic fatty liver disease and on severity of liver disease and of glucose and lipid dysmetabolism. Musso G, Bo S, Cassader M, De Michieli F, Gambino R, Am J Clin Nutr 2013 98 895 906
44. Genetic variants in PNPLA3 and risk of non-alcoholic fatty liver disease. Peng XE, Wu YL, Lin SW, Lu QQ, Hu ZJ, Lin X, Plos One 2012 7 50256
45. A common variant in the PNPLA3 gene is a risk factor for non-alcoholic fatty liver disease in obese Taiwanese children. Lin YC, Chang PF, Hu FC, Yang WS, Chang MH, Ni YH, J Pediatr 2011 158 740 744
46. The l148 PNPLA3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls. Valenti L, Rametta R, Ruscica M, Dongiovanni P, Steffani L, Motta BM, Canavesi E, Fracanzani AL, Mozzi E, Roviaro G, Magni P, Fargion S, BMC Gastroenterol 2012 12 111
47. Role of adiponectin in the metabolic syndrome: current perspectives on its modulation as a treatment strategy. Padmalayam I, Suto M, Curr Pharm Des 2013 19 5755 5763
48. Adiponectin-a key adipokine in the metabolic syndrome. Whitehead JP, Richards AA, Hickman IJ, Macdonald GA, Prins JB, Diabetes Obes Metab 2006 8 264 280
49. Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases. Yamauchi T, Kadowaki T, Int J Obes 2008 32 Suppl 7 13 18
50. The PI(A1/A2) polymorphism of glycoprotein IIIa and cerebrovascular events in hypertension: Increased risk of ischemic stroke in high-risk patients. Lanni F, Santulli G, Izzo R, Rubattu S, Zanda B, Volpe M, Iaccarino G, Trimarco B, J Hypertens 2007 25 551 556 (Pubitemid 46213792)
51. The GPIIIa PIA2 polymorphism is associated with an increased risk of cardiovascular adverse events. Galasso G, Santulli G, Piscione F, De Rosa R, Trimarco V, Piccolo R, Cassese S, Iaccarino G, Trimarco B, Chiariello M, BMC Cardiovasc Disord 2010 10 41
52. CaMK4 gene deletion induces hypertension. Santulli G, Cipoletta E, Sorriento D, Del Giudice C, Anastasio A, Monaco S, Maione AS, Condorelli G, Puca A, Trimarco B, Illario M, Iaccarino G, J Am Heart Assoc 2012 1 001081
53. Overweight, physical activity, tobacco and alcohol consumption in a cross-sectional random sample of German adults. Haenle MM, Brockmann SO, Kron M, Bertling U, Mason RA, Steinbach G, Boehm BO, Koenig W, Kern P, Piechotowski I, Kratzer W, EMIL-Study group, BMC Public Health 2006 6 233
54. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr, International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity, Circulation 2009 120 1640 1645
55. AGA technical review on nonalcoholic fatty liver disease. Sanyal AJ, Gastroenterolgy 2002 123 1705 1725 (Pubitemid 35231670)
56. Prevalence and risk factors of focal sparing in hepatic steatosis. Kratzer W, Akinli AS, Bommer M, Arnold F, Eggink S, Imhof A, Mason RA, Klaus J, Schuler A, Boehm BO, Haenle MM, Ultraschall Med 2010 31 37 42